Research suggests that GLP-1 receptor agonism may reduce the production of pro-inflammatory cytokines, decrease oxidative stress, and potentially influence the balance between pro-inflammatory and regulatory T cell populations
Zhu W, Ding C, Huang P et al (2022) Metformin ameliorates hepatic steatosis induced by olanzapine through inhibiting LXR/PCSK9 pathway
Not appropriate for people with any of the following: Your provider will review your history and labs and discuss alternatives if semaglutide is not a fit
CagriSema (semaglutide + cagrilintide), filed by Novo Nordisk in December 2025, achieved 22.7% weight loss in trials and could receive FDA approval in 2026
6 Compared with placebo, semaglutide has been shown to result in greater improvements in cardiometabolic risk factors such as waist circumference, blood pressure, lipid levels, and A1C levels